PMID- 30793254
OWN - NLM
STAT- MEDLINE
DCOM- 20191004
LR  - 20210109
IS  - 1179-1950 (Electronic)
IS  - 0012-6667 (Linking)
VI  - 79
IP  - 4
DP  - 2019 Mar
TI  - Erenumab for Preventive Treatment of Migraine: A Systematic Review and 
      Meta-Analysis of Efficacy and Safety.
PG  - 417-431
LID - 10.1007/s40265-019-01069-1 [doi]
AB  - BACKGROUND: Novel therapeutic options with improved efficacy and safety profiles 
      are needed for the prophylaxis of migraine. In recent years, the inhibition of 
      calcitonin gene-related peptide (CGRP) signaling has attracted growing interest 
      in the pharmacological research on migraine. Erenumab is the first fully human 
      monoclonal antibody directed against the CGRP receptor to be approved for use in 
      migraineurs. OBJECTIVE: To evaluate the efficacy and safety of erenumab as 
      preventive treatment in patients with migraine using meta-analytical techniques. 
      METHODS: Randomized, placebo-controlled, single- or double-blinded trials were 
      identified through a systematic literature search (October week 4, 2018). Main 
      outcomes included the changes from baseline in monthly migraine days (MMD) and 
      monthly acute migraine-specific medication days (MSMD) at week 12, and the 
      incidence of adverse events (AEs), severe AEs (SAEs) and treatment withdrawal due 
      to AEs. Mean difference (MD) and risk ratio (RR) with 95% confidence intervals 
      (95% CIs) were estimated. RESULTS: Across the five included trials, erenumab 
      given as a subcutaneous injection at a monthly dosage of 70 mg and 140 mg was 
      associated with a significantly greater reduction in baseline MMD (70 mg: MD - 
      1.3, 95% CI - 1.7 to - 1.0, p < 0.001; 140 mg: MD - 1.9, 95% CI - 2.3 to - 1.4, 
      p < 0.001) and MSMD (70 mg: MD - 1.0, 95% CI - 1.6 to - 0.4, p < 0.001; 140 mg: 
      MD - 1.8, 95% CI - 2.5 to - 1.1, p < 0.001) than placebo. There were no 
      differences in the occurrence of AEs, SAEs, and drug withdrawal due to AEs 
      between the erenumab and placebo groups. CONCLUSIONS: Erenumab is an efficacious 
      and well tolerated preventive treatment in adult patients with episodic and 
      chronic migraine.
FAU - Lattanzi, Simona
AU  - Lattanzi S
AUID- ORCID: 0000-0001-8748-0083
AD  - Neurological Clinic, Department of Experimental and Clinical Medicine, Marche 
      Polytechnic University, Via Conca 71, 60020, Ancona, Italy. 
      alfierelattanzisimona@gmail.com.
FAU - Brigo, Francesco
AU  - Brigo F
AD  - Department of Neuroscience, Biomedicine and Movement Science, University of 
      Verona, Verona, Italy.
AD  - Division of Neurology, "Franz Tappeiner" Hospital, Merano, BZ, Italy.
FAU - Trinka, Eugen
AU  - Trinka E
AD  - Department of Neurology, Christian Doppler Klinik, Paracelsus Medical University, 
      Salzburg, Austria.
AD  - Center for Cognitive Neuroscience, Salzburg, Austria.
AD  - Public Health, Health Services Research and HTA, University for Health Sciences, 
      Medical Informatics and Technology, Hall in Tirol, Austria.
FAU - Vernieri, Fabrizio
AU  - Vernieri F
AD  - Neurology Unit, Campus Bio-Medico University, Rome, Italy.
FAU - Corradetti, Tommaso
AU  - Corradetti T
AD  - Neurological Clinic, Department of Experimental and Clinical Medicine, Marche 
      Polytechnic University, Via Conca 71, 60020, Ancona, Italy.
FAU - Dobran, Mauro
AU  - Dobran M
AD  - Clinic of Neurosurgery, Department of Experimental and Clinical Medicine, Marche 
      Polytechnic University, Ancona, Italy.
FAU - Silvestrini, Mauro
AU  - Silvestrini M
AD  - Neurological Clinic, Department of Experimental and Clinical Medicine, Marche 
      Polytechnic University, Via Conca 71, 60020, Ancona, Italy.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
PL  - New Zealand
TA  - Drugs
JT  - Drugs
JID - 7600076
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (Calcitonin Gene-Related Peptide Receptor Antagonists)
RN  - I5I8VB78VT (erenumab)
RN  - JHB2QIZ69Z (Calcitonin Gene-Related Peptide)
SB  - IM
MH  - Antibodies, Monoclonal, Humanized/adverse effects/*therapeutic use
MH  - Calcitonin Gene-Related Peptide/analogs & derivatives
MH  - Calcitonin Gene-Related Peptide Receptor Antagonists/therapeutic use
MH  - Humans
MH  - Injections, Subcutaneous
MH  - Migraine Disorders/*drug therapy
MH  - Randomized Controlled Trials as Topic
MH  - Treatment Outcome
EDAT- 2019/02/23 06:00
MHDA- 2019/10/08 06:00
CRDT- 2019/02/23 06:00
PHST- 2019/02/23 06:00 [pubmed]
PHST- 2019/10/08 06:00 [medline]
PHST- 2019/02/23 06:00 [entrez]
AID - 10.1007/s40265-019-01069-1 [pii]
AID - 10.1007/s40265-019-01069-1 [doi]
PST - ppublish
SO  - Drugs. 2019 Mar;79(4):417-431. doi: 10.1007/s40265-019-01069-1.